IRWD Rises 307% in 6 Months: Is This an Indication to Buy the Stock?

Key Takeaways IRWD shares have jumped 307.3% in six months, outpacing its industry, the sector and the S&P 500.Ironwood expects 2026 revenues of $450-$475M, up 54% Y/Y at midpoint, with EBITDA above $300M.Ironwood is advancing apraglutide toward a phase III study in 1H26 following an FDA meeting.Shares of Ironwood Pharmaceuticals (IRWD) have risen sharply over the past six months, primarily driven by the improving demand for its sole marketed product, Linzess (linaclotide) and the company’s upbeat 2026 reve ...